Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype

Antimicrob Agents Chemother. 2006 Sep;50(9):3227-8. doi: 10.1128/AAC.00551-06.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antifungal Agents / pharmacokinetics*
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP2C9
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism
  • Genotype
  • Humans
  • Mixed Function Oxygenases / genetics
  • Mixed Function Oxygenases / metabolism
  • Pyrimidines / pharmacokinetics*
  • Triazoles / pharmacokinetics*
  • Voriconazole

Substances

  • Antifungal Agents
  • Pyrimidines
  • Triazoles
  • Cytochrome P-450 Enzyme System
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Voriconazole